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Introduction: Although consensus guidelines recommend checking serum B12 in patients with 
dementia, clinicians are often faced with various questions: (1) Which patients should be tested? 
(2) What test should be ordered? (3) How are inferences made from such testing? (4) In addition to 
serum B12, should other tests be ordered? (5) Is B12 deficiency compatible with dementia of the 
Alzheimer’s type? (6) What is to be expected from treatment? (7) How is B12 deficiency treated?
Methods: On January 31st, 2009, a Medline search was performed revealing 1,627 citations 
related to cobalamin deficiency, hyperhomocysteinemia, and dementia. After limiting the search 
terms, all abstracts and/or articles and other references were categorized into six major groups 
(general, biochemistry, manifestations, associations and risks, evaluation, and treatment) and 
then reviewed in answering the above questions.
Results: The six major groups above are described in detail. Seventy-five key studies, series, 
and clinical trials were identified. Evidence-based suggestions for patient management were 
developed.
Discussion: Evidence is convincing that hyperhomocysteinemia, with or without hypovitamino-
sis B12, is a risk factor for dementia. In the absence of hyperhomocysteinemia, evidence is less 
convincing that hypovitaminosis B12 is a risk factor for dementia. B12 deficiency manifestations 
are variable and include abnormal psychiatric, neurological, gastrointestinal, and hematological 
findings. Radiological images of individuals with hyperhomocysteinemia frequently demonstrate 
leukoaraiosis. Assessing serum B12 and treatment of B12 deficiency is crucial for those cases 
in which pernicious anemia is suspected and may be useful for mild cognitive impairment and 
mild to moderate dementia. The serum B12 level is the standard initial test: 200 picograms per 
milliliter or less is low, and 201 to 350 picograms per milliliter is borderline low. Other tests 
may be indicated, including plasma homocysteine, serum methylmalonic acid, antiparietal cell 
and anti-intrinsic factor antibodies, and serum gastrin level. In B12 deficiency dementia with 
versus without pernicious anemia, there appear to be different manifestations, need for further 
workup, and responses to treatment. Dementia of the Alzheimer’s type is a compatible diagnosis 
when B12 deficiency is found, unless it is caused by pernicious anemia. Patients with pernicious 
anemia generally respond favorably to supplemental B12 treatment, especially if pernicious 
anemia is diagnosed early in the course of the disease. Some patients without pernicious anemia, 
but with B12 deficiency and either mild cognitive impairment or mild to moderate dementia, 
might show some degree of cognitive improvement with supplemental B12 treatment. Evidence 
that supplemental B12 treatment is beneficial for patients without pernicious anemia, but with 
B12 deficiency and moderately-severe to severe dementia is scarce. Oral cyanocobalamin is 
generally favored over intramuscular cyanocobalamin.
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Introduction
The notion of vitamin B12 deficiency (ie, B12 hypovitaminosis), 
its psychiatric and neurological manifestations, and its 
treatment is an age-old issue that has generated much 
controversy over many years. Although consensus 
guidelines1–4 recommend checking serum B12 levels in 
patients with dementia, clinicians are often faced with 
questions regarding how to interpret and what to do with 
the results.5 In order to help in clarifying these uncertain-
ties, six questions were posed and then answered: 1) In 
which patients should vitamin B12 be routinely assessed? 2) 
What test or tests should be ordered, and how are inferences 
made from such testing? 3) Does the finding of low serum 
B12 or elevated homocysteine (Hcy) require evaluation for 
other medical conditions? 4) When vitamin B12 deficiency 
is found in dementia, is dementia of the Alzheimer’s type 
(DAT) a compatible diagnosis? 5) Based on the benefit-to-
risk ratio in treatment of dementia, if vitamin B12 deficiency 
is determined, should supplemental B12 be initiated? 6) How 
is vitamin B12 deficiency treated?
By assimilating data from in vitro, in vivo animal, and 
in vivo human studies and epidemiological studies, this article 
clarifies these and other issues regarding hypovitaminosis 
B12, hyperhomocysteinemia (HHcy), and dementia.
Methods/results
The study design is a qualitative and quantitative review of the 
literature. The problem discussed is that in clinicians’ geriatric 
practices, patients with dementia and low vitamin B12 were 
not showing significant improvement with supplemental B12 
therapy. Our hypothesis is that patients with dementia and low 
vitamin B12 improve with supplemental B12 therapy. The 
null hypothesis is that patients with dementia and low vitamin 
B12 do not improve with supplemental B12 therapy.
On January 31st, 2009 a Medline search was performed 
using the search terms: (Alzheimer OR Alzheimer’s OR 
dementia OR cognitive impairment OR cognitive dysfunction) 
AND (cobalamin OR cyanocobalamin OR B12 OR B-12 OR 
B 12 OR homocysteine OR hyperhomocysteinemia OR homo-
cystinuria), which revealed 1,627 citations. “Title/Abstract” 
field limits decreased the search to 1,095 citations, which 
included 230 review articles. Using a Boolean operation, the 
review articles were removed, reducing the search to 865 cita-
tions. Subsequently, the search was limited to only citations 
with abstracts, so as to exclude publications such as ‘Letters 
to the Editor’ and case reports, which revealed 824 citations. 
Furthermore, in order to not miss any positive findings of 
individual case reports or case series, on September 6th, 2009 
another Medline search was performed using the search terms: 
pernicious anemia AND dementia AND (case report OR case 
series) revealing 20 citations. Of the 844 articles, all abstracts 
were reviewed and, when useful, relevant articles were obtained 
and reviewed. Bibliographies from relevant articles were 
reviewed and, when applicable, review articles, ‘Letters to the 
Editor,’ and case reports were included in the overall review. 
Data from (1) other Medline searches, (2) Internet searches, 
(3) basic and clinical science textbooks, and (4) personal com-
munications were added for clarification of technical issues. 
All abstracts, articles, and other references were categorized, 
allowing duplications, into six major categories: (1) general 
information, (2) biochemical evidence suggesting that hypo-
vitaminosis B12 or HHcy are causal factors in dementia, 
(3) clinical and radiological manifestations, (4) associations 
between hypovitaminosis B12 or HHcy and cognitive impair-
ment, (5) evaluation, and (6) treatment. Endnote version X.0.2 
(Thomson Reuters, Philadelphia, PA) was used to maintain the 
reference library, which contained 839 citations. Evidenced-
based medicine was used to develop suggestions for vitamin 
B12 workup and treatment in patients with suspected mild 
cognitive impairment (MCI) or dementia.
There are 511 articles and other references relevant to the 
six questions posed in the introduction and the six major cat-
egories listed above. Question 5 in the Introduction considers 
treatment benefits and risks. In terms of treatment benefits, 
the study objective was to determine whether or not vitamin 
B12 is beneficial for B12-deficient dementia. Letting the null 
hypothesis be, “Patients with dementia and low vitamin B12 
do not improve with supplemental B12 therapy,” not reject-
ing the null hypothesis when it is not true would be a type 2 
error (false negative). In order to avoid a type 2 error, thus 
concluding B12 treatment is not beneficial, when in truth 
it is beneficial, all published studies and reports contained 
in Medline (Box 1), including case series, in which supple-
mental B12 was an exposure and cognitive change was an 
outcome are included in the discussion and tables (N = 38), 
regardless of the quality of the study or number of subjects. 
Also included are all published cohort and longitudinal 
studies in Medline, where exposure pertains to metabolic 
or serum B12 deficiency and outcomes pertain to change in 
cognitive function or development or prevention of dementia 
(N = 37). Also included are the majority of the retrospective 
and cross-sectional studies in Medline that examine similar 
outcomes and exposures. Articles pertaining to genetics, 
biochemistry, pathophysiology, clinical manifestations, and 
radiological manifestations illuminating our understanding 
on relationships between HHcy with and without cobalamin Neuropsychiatric Disease and Treatment 2010:6 161
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Table 1 Causes of hyperhomocysteinemia and B12 deficiency
Causes of hyperhomocysteinemia
  •  Genetic deficiencies and polymorphisms52,58
      methylenetetrahydrofolate reductase
      methionine synthetase
      cystathionine beta-synthetase
  •  Drugs
      levodopa (l-dopa) – due to its metabolism46,51,54
      nitrous oxide – due to methionine synthetase inhibition48,49,53
      others
  •  Nutritional deficiencies
      vitamin B6
      folate
      vitamin B12 (caused by pernicious anemia, celiac disease, and others)
  •  Other factors7,18,19,39,52,57,59–61
      advanced age
      male gender
      renal insufficiency
Causes of B12 deficiency45,47,50,55,56,62
  •    Genetic deficiencies of intrinsic factor – due to inability to absorb 
B12 at the distal ileum
  •    Genetic deficiencies or polymorphisms of transcobalamin II – due 
to inability or impediment of B12 cellular uptake
  •  Diseases affecting salivary glands – due to r-protein hyposecretion
  •    Gastric disease, resection, or bypass surgery – due to lack of 
hydrochloric acid and pepsin, which are required to separate animal 
protein from dietary B12, causing food-cobalamin malabsorption  
(eg, Helicobacter pylori infection)
  •    Diseases affecting gastric parietal cells – due to hyposecretion and 
inhibition of intrinsic factor (eg, pernicious anemia)
  •    Diseases affecting the pancreas and upper small intestine – due 
to lack of pancreatic enzymes and insufficient elevation of pH, 
which are required to separate r protein from B12 (eg, pancreatic 
insufficiency and ileal resection)
  •    Ileal disease or resection – due to specific inability to absorb the 
intrinsic factor-B12 complex (eg, celiac disease)
  • various malabsorption syndromes
  •  Medications
     histamine type 2 receptor blockers
     protein pump inhibitors
  •  Dietary deficiencies (eg, vegetarian diet)
  • Advancing age
Box 1 Studies and reports in which supplemental B12 is an 
exposure and cognitive change is an outcome
Abyad, 2002 Fox, 1975 McMahon, 2006
Aisen, 2008 Healton, 1991 Nilsson, 2001
Bolaman, 2003 Hvas 2004 Osimani, 2005
Bryan, 2002 ikeda, 1992 remington, 2009
Carmel, 1995 Kalita, 2008 Seal, 2002
Clarke, 2003 Kwok, 1998 Stott, 2005
Crystal, 1994 Kwok, 2008 Sun, 2007
Cunha, 1990 La rue, 1997 Teunisse, 1996
Cunha, 1995 Lehmann, 2003 van Asselt, 2001
eastley, 2000 Levine 2006 van Dyck, 2008
el Otmani, 2008 Lin, 2008 van Uffelen, 2008
eussen, 2006 Lindenbaum, 1988 Wolters, 2005
Fourniere, 1997 Martin, 1992
deficiency and dementia are included in the review, as are 
articles relevant to evaluation, prognosis, and treatment.
Discussion
General information
Vitamin B12 is composed of a central cobalt atom, attached 
to a dimethylbenzimidazole group, four nitrogen atoms, each 
pertaining to four pyrrole rings, and an R group (-CN, -OH, 
-CH3, or adenosyl group), denoting the specific type of 
cobalamin.6–8 The definition of vitamin B12 deficiency is a 
quantitative lack of vitamin B12 in the diet, body fluids, or 
cells or a qualitative lack of intracellular B12 utilization.
B12 deficiency occurs in roughly 10% of general9–23 and 
17% of demented10,24–26 elderly populations. B12 deficiency 
in demented individuals ranges from one10,27,28 to five25,29 
times that of controls. Serum B12 levels and cerebral spinal 
fluid (CSF) folate levels decrease with advancing age,9–12,30–34 
whereas serum folate levels may either increase or decrease 
with age.32 Hcy is a nonessential thiol amino acid.35,36 HHcy is 
defined as an abnormally high level of total Hcy in the plasma. 
HHcy occurs in 6% to 81% of individuals, depending on the 
population studied.37–44 Causes of HHcy and B12 deficiency 
are listed in Table 1.7,18,19,39,45–62 Further details regarding 
differential diagnoses are available on the Internet.62
Biochemical evidence suggesting 
that hypovitaminosis B12 
or hyperhomocysteinemia are causal  
factors in dementia
The means by which HHcy is involved in dementia may 
possibly be explained by aging and reduced vitamin B12 
or folate supply versus demand ratio,63,64 with functional, 
structural, genetic, and nutritional determinants. Possible 
functional determinants include Hcy agonism of N-methyl-
D-aspartic acid (NMDA) receptors, which causes exces-
sive intracellular calcium influx and neuronal death65,66 
and HHcy creating a state of hypomethylation in the 
pathogenesis of Alzheimer’s disease (AD),21,58,67 causing 
deoxyribonucleic acid (DNA) damage and apoptosis.68–71 
HHcy inhibits adult mammal hippocampal neurogen-
esis.72 Hcy may compete with gamma-amino butyric acid 
(GABA) at the GABA receptor and may affect its inhibi-
tory function.73,74Neuropsychiatric Disease and Treatment 2010:6 162
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Potential structural determinants include HHcy causing 
blood–brain barrier (BBB) dysfunction75–78 and endothelial 
cell toxicity,47,64 whereby Hcy changes endothelial cell 
surface properties from anticoagulant to procoagulant.47,52,73,79 
Genetic determinants include various polymorphisms 
and homozygous monogenic deficiencies, involving 
methylenetetrahydrofolate reductase (MTHFR), trans-
cobalamin (TC) II, methionine synthetase (MS), and 
cystathione beta-synthetase (CBS). These may contribute 
to hypovitaminosis B12, HHcy, and dementia.7,47,52,64,73,80–82 
Meta-analyses83–89 of the MTHFR polymorphism show that 
those with 677 TT alleles compared to 677 CC alleles have 
elevated Hcy and increased risk for myocardial infarction 
(MI), transient ischemic attack, and stroke. Hyperhomocys-
teinemic individuals with certain butyrylcholinesterase-K 
(BuChE-K) alleles cognitively decline more rapidly than 
those with wild-type BuChE alleles.90 Nutritional deter-
minants include decreased vitamin B12 ingestion9,45,47 and 
food-cobalamin malabsorption.9,15,19,45,49,91–93
In vitro, in vivo animal, and in vivo human studies 
suggest AD pathophysiology conceivably involves 
a hypomethylation state,67,94–97 reactive oxygen spe-
cies (ROS) generation,27,98–101 immune activation,102–110 
and anomalous protein development.111 Abnormal Hcy 
metabolism is involved in each of these four processes. 
Hcy is metabolized by the methionine cycle and trans-
sulfuration pathway (Figure 1),112 where it has one of 
three possible fates: methylation to methionine (Met), 
transsulfuration to cystathionine, or adenosylation to 
S-adenosylhomocysteine (SAH).113,114 With normal Hcy 
levels, the first two reactions are maintained, the first occur-
ring in the brain and body and the second predominately 
occurring in the body, promoting homeostatic methylation 
reactions and maintaining healthy cells. With Hcy elevation 
the third reaction ensues, promoting a hypomethylation state 
leading to disease.115
On the one hand, without oxidative chemical reactions, 
as the basis for cellular respiration, we would not have life, 
at least as we know it. On the other hand, without these reac-
tions, we would not have ROS.116 There are thousands of 
publications related to ROS and aging, the greatest known risk 
factor for sporadic AD.114,116,117 Oxidative metabolism gener-
ates a very small fraction of ROS,117 which can be beneficial 
or detrimental to the central nervous system. Oxidative stress 
occurs when ROS generation exceeds ROS defense,118 leading 
to potential molecular and cellular damage.117 Aberrant 
mitochondrial enzymes may facilitate this process, thereby 
contributing to the pathophysiology of AD.116
Hcy  is  rapidly  auto-oxidized  to  homocysteine 
thiolactone, homocystine, and mixed disulfides,7,119 
producing ROS,18,21,47,52,68,120 including singlet oxygen, 
superoxide anions, hydroxyl radicals, and hydrogen 
peroxide.21,42,52,68,117,118 Hcy elevation is associated with 
microglia activation and proliferation71 and immune 
activation and deposition,108 which is associated with 
choroid plexus dysfunction,121–123 possibly impeding 
vitamin B12123–125 and folate122,125 influx to, and amyloid 
beta (Aβ) peptide123,126,127 clearance from, brain tissue in 
AD. In certain systems, Hcy elevation leads to amyloid 
precursor128 and tau128–132 protein hyperphosphorylation, 
and Hcy oxidation produces products that crosslink with 
Aβ and tau proteins, causing their precipitation.119,128,133 Hcy 
elevation is associated with increased Aβ peptide, in both 
brain134 and plasma.51,135,136
A deleterious cycle may occur between ROS generation 
and immune activation, where the former may cause the 
latter137–139 and vice versa.63,64,140–144
Hcy may promote a means for such a cycle,64,106,120 
because  ROS  generation  is  associated  with  Hcy 
elevation,120,142,145–147 which is associated with immune 
activation,64,71,79,148–150 and immune activation is associated 
with Hcy elevation,64,142,151,152 which is associated with 
ROS generation (Figure 2).47,64,71,153–155 Additional evidence 
verifies ROS,145,151,156 hypomethylation,21,58,67,94,95,128,136,157 
immunological components,64,79,106,109,110,142 and Aβ and tau 
proteins58,65,66,120,136,158 interact with one another, produc-
ing a neurodegeneration cascade in AD. ROS generation 
precedes both Aβ peptide deposition159–162 and tau-associ-
ated neurodegeneration.163 ROS generation deregulates 
tau protein phosphorylation,164,165 and is associated with 
decreased S-adenosylmethionine (SAM),120 increased SAH, 
a decreased SAM/SAH ratio,115 and hyperconsumption 
and depletion of antioxidants98,151,156 and tetrahydrofolate 
(THF).64,120,151,156,166
With absolutely or relatively low folate or vitamin B12, 
MS-mediated Hcy clearance is impeded,52,120 resulting in 
a hypomethylation state. Also, Hcy elevation may lead to 
hyperconsumption and depletion of vitamin B12 in various 
cases of AD and vascular dementia (VaD).146 Hcy potentiates 
Aβ peptide-induced ROS generation and apoptosis.69,154,155,167 
Aβ and tau proteins are concentrated sources for further ROS 
generation, Hcy elevation, and immune activation, thereby 
perpetuating the deleterious cycle.120,143,168–170 Also, in vivo 
human studies show that free cobalt is elevated in individuals 
with AD compared to controls.8 In vitro studies show free 
cobalt generates oxidative stress, as measured by reduced Neuropsychiatric Disease and Treatment 2010:6 163
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Figure 1 Folate cycle, methionine cycle,  and transsulfuration pathway. Copyright © 2005.   Adapted with permission from Davis Sr, Quinlivan eP,  Shelnutt KP, et al. Homocysteine 
synthesis is elevated but total remethylation is unchanged by the methylenetetrahydrofolate reductase 677C-T polymorphism and by dietary folate restriction in young 
women.  J Nutr. 2005;135(5):1045–1050. 
Notes: This schematic is of the folate cycle (left), methionine cycle (right), and transsulfuration pathway (bottom), with homocysteine being the common substance to all three. 
Folic acid (synthetic) is converted by DHFr to dihydrofolic acid (dietary), which is converted by DHFr to THF, which enters the folate cycle: THF → N5,N10-methylene THF → 
N5-methyl THF → THF. in this last step, vitamin B12 is required as a cofactor for MS. With low or absent vitamin B12, this last step is hindered leading to the methylfolate trap 
with elevated CH3-THF. Homocysteine metabolism: homocysteine is produced in the methionine cycle by the deadenosylation/hydration of AdoHcy, and is either remethyl-
ated to methionine, by the methionine cycle or catabolized to cysteine, by the transsulfuration pathway. Note the AdoHcy deadenosylation/hydration to Hcy is a reversible 
reaction favoring homocysteine adenosylation/hydration to AdoHcy. Methyl groups produced by AdoMet demethylation to AdoHcy are used for nucleic acid, protein, lipid, and 
neurotransmitter biosynthesis. Cysteine is a nonessential amino acid used in the biosynthesis of proteins, glutathione, coenzyme A, taurine, and inorganic sulfur. Glutathione 
is an antioxidant that protects cells from rOS.
Abbreviations: AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; BHMT, betaine-homocysteine methyltransferase; CBS, cystathionine β-synthase; 
CGL, cystathionine gamma-lyase; CH2THF, methylenetetrahydrofolate; -CH3, methyl group; CH3THF methyl tetrahydrofolate; DHFr, dihydrofolate reductase; MAT, methionine 
adenosyltransferases; MS, methionine synthase; MTHFr, methylenetetrahydrofolate reductase; PLP, pyridoxal phosphate (the active form of vitamin B6, pyridoxine); rOS, reactive 
oxygen species; SAHH, S-adenosylhomocysteine hydrolase; SHMT, serine hydroxymethyltransferase; THF, tetrahydrofolate.
glutathione, increases Aβ peptide secretion, and produces 
neuroblastoma cytotoxicity.8,120
Within the central nervous system, a balance may 
occur between endogenous neurotoxic agents on one 
hand and endogenous neurotrophic agents on the other 
hand.171 Examples of potential neurotoxic agents include 
tumor necrosis factor-alpha (TNF-α), nerve growth factor 
(NGF), and the soluble CD40-soluble CD40 ligand dyad 
(sCD40-sCD40). Examples of potential neurotrophic agents 
include interleukin-6 (IL-6), epidermal growth factor 
(EGF), and transforming growth factor-beta1 (TGF-β1). 
In animals, if the balance is tilted in favor of TNF-α, NGF, 
and sCD40-sCD40 (eg, by the administration of exogenous 
TNF-α),172 as opposed to IL-6, NGF, and TGF-β1, then the 
morphological changes of subacute combined degeneration 
(SCD) are observed: white matter interstitial edema, intra-
myelinic edema, spongy vacuolation, and astrogliosis.172–175 
Vitamin B12-depleted animals exhibit increased levels 
of TNF-α, NGF, and sCD40-sCD40172,176 and decreased 
levels of IL-6 and EGF,176 thereby tilting the balance and 
developing the myelopathic changes of SCD. Not only 
does treatment with vitamin B12 reduce or reverse these 
changes,172,175 but treatment with anti-TNF-α antibodies, 
IL-6, EGF, and TGF-β1 does so as well.172,176 Interest-
ingly, a similar observation has been observed in humans. 
Serum TNF-α is higher and serum EGF is lower in subjects 
with severe B12 deficiency compared to controls, where a 
↑ Hcy
↑ Hcy
ROS
Immune
activation 
Figure 2 illustration of a biologically plausible deleterious cycle of reactive oxygen 
species (rOS), homocysteine (Hcy), and immune activation that possibly may be 
involved in the pathogenesis of Alzheimer’s disease.Neuropsychiatric Disease and Treatment 2010:6 164
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direct correlation is found between plasma Hcy and serum 
TNF-α.173 The association is translative into the CSF, where 
CSF B12 and EGF are lower and CSF Hcy and TNF-α 
are higher in subjects with SCD compared to non-B12 
deficient controls.177 B12-repletion lowers serum TNF-α 
and raises serum EGF, thereby normalizing the imbalance, 
which occurs concomitantly with clinical and hematologi-
cal disease remission.173 Hence, in addition to well-known 
enzymatic roles for vitamin B12, it is thought to also have 
nonenzymatic roles, where it is associated with downgrad-
ing synthesis and release of TNF-α and upgrading synthesis 
and release of EGF.173,177,178
Clinical and radiological manifestations
Clinical manifestations of low vitamin B12 include abnor-
mal psychiatric, neurological, and gastrointestinal findings. 
Psychiatric manifestations consist of psychoses, including 
paranoia, delusions, and hallucinations,23,58,179–184 cognitive 
dysfunction, including memory impairment, delirium, and 
dementia,7,21,23,49,58,93,180,181,185–188 and affective syndromes, 
including mania and depression,7,21,23,58,93,180,181,186,189–191 which 
also occurs with elevated Hcy192–194 and low SAM.67,192 Asso-
ciations exist between HHcy and cognitive dysfunction in 
bipolar disorder195–197 and perhaps schizophrenia.198 Neuro-
logical manifestations include myelopathy and peripheral, 
autonomic, and optic neuropathies.199 Paresthesia is caused 
by a sensory lesion anywhere between the peripheral nerve 
and brain and is often the initial symptom.23,58,92,180,181,188 
SCD refers to myelopathy affecting posterior and lat-
eral columns, characterized by a pernicious sequence of 
vacuolar demyelination, axonal degeneration, and neuronal 
death.18,58,200–202 Posterior column myelopathy affects affer-
ent pathways, causing the most common neurological signs: 
ataxia, diminished proprioception and vibratory senses, and 
presence of Romberg’s sign.18,49,58,180,185,188,200,201,203 Lateral 
column myelopathy affects efferent pathways, causing the 
second most common neurological signs: extremity muscular 
weakness, spasticity, hyperactive reflexes, and Babinski’s 
sign.18,49,58,180,181,200,201 Peripheral and autonomic neuropa-
thies cause hypoactive reflexes, sensory loss, orthostatic 
hypotension, fecal and urinary incontinence, and impo-
tence.18,23,49,58,92,180,181,185,188,200,203 Although optic neuropathy 
is uncommon,23,58,180,203 visual impairment may occasionally 
be the earliest or sole manifestation of the disease.203 Gas-
trointestinal manifestations include epithelial atrophy of the 
tongue, referred to as atrophic glossitis, which causes the 
tongue to be sore and beefy red,18,23 and epithelial atrophy 
of the stomach.15
Computerized axial tomographic (CAT) and magnetic 
resonance imaging (MRI) scans of nondemented elderly 
brains may show age-related cerebral atrophy and various 
grades of periventricular white matter disease consistent with 
chronic microvascular ischemia.204–208 Although linear and 
volume measurement methods, evaluating ventricle-to-brain 
ratios and medial temporal lobe atrophy, reveal significant 
differences in group means, between those with AD and 
controls,205,207,209–217 such strategies are not recommended for 
the purpose of diagnosing AD.3,218 Assuming normal distribu-
tions of both nondemented and demented groups, a certain 
degree of overlap may exist,205,207,216 unless specified by scan 
angle-adjusted temporal lobe neuroimaging.207,214 Even so, 
such imaging may not distinguish non-Alzheimer’s demen-
tia from controls.217 Although CAT scans of nondemented 
elderly commonly show age-related cerebral atrophy, those 
of demented elderly often show cerebral atrophy more than 
expected for age,210 and are read as variably judged atro-
phy and differently interpreted white matter changes.218,219 
Whether or not such findings relate to dementia with low 
vitamin B12 and/or elevated Hcy is often unclear.
Accordingly, a literature review finds radiological mani-
festations of low vitamin B12 and/or elevated Hcy to include 
leukoaraiosis, brain atrophy, and silent brain infarcts.199,220–237 
Leukoaraiosis is a radiological term that refers to brain 
white matter hypodensity on CAT scans or hyperintensity 
on T2-weighted magnetic resonance imaging (MRI).238 It is 
associated with aging,221,230,239–244 chronic microvascular hypo-
perfusion,245 BBB dysfunction,246 hypertension,221,230,240,241,242,244 
stroke,230,239,240–242,244,247 and death.239 Leukoaraiosis is described 
pathologically as periventricular leukoencephalopathy 
or subcortical arteriosclerotic encephalopathy; it occurs 
in brains of individuals with AD243 and dementia of the 
Binswanger type (DBT),248 which is a relatively rarer type 
of dementia and is associated with other findings. HHcy 
increases the risk for leukoaraiosis.220,221,223–226,228,230,232,236 
Independently from plasma Hcy levels, one cross-sectional 
study249 found an inverse association between the concen-
tration of normal range serum B12 levels and the degree 
of leukoaraiosis; nonetheless, in the absence of HHcy, two 
studies227,231 found low serum B12 does not increase the risk 
for leukoaraiosis. Parenthetically, one prospective study250 
found an inverse association between serum folate levels and 
the degree of leukoaraiosis. Although leukoaraiosis is more 
prevalent in demented than nondemented individuals225,247 
and it increases the risk for developing dementia,247,248,251 
results are mixed in terms of whether or not the link between 
HHcy and cognitive dysfunction is specifically mediated by Neuropsychiatric Disease and Treatment 2010:6 165
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leukoaraiosis.228,232,240,243,252–255 In both cross-sectional and 
prospective evaluations, hypovitaminosis B12 and HHcy 
are associated with brain atrophy.199,222,229,232,234,237 HHcy is 
associated with silent brain infarcts.232
VaD,61 DBT,256 and AD,61,222,243,257–259 represent various 
spectra of vascular pathology. To illustrate, cerebral amy-
loid angiopathy occurs in many cases of DBT248 and in 
most cases of AD,46,260,261 where increased vessel atrophy,262 
decreased microvascular density,262 reduced temporal lobe 
blood flow,263,264 and spontaneous cerebral emboli265,266 
are other significant findings. Hcy permeates through the 
BBB,267,268 causing BBB dysfunction,74,76–78 which is observed 
in AD,247,269 DBT,220,223,256,270 and VaD,75 allowing easy influx 
for a wide variety of proteins to cerebral interstitial fluid271,272 
and vice versa.273 With BBB dysfunction, brain parenchyma 
likely becomes less protected from toxic effects of systemic 
HHcy,229 which increases risk for acute macrovascular dis-
ease, or strokes,7,21,70,84,85,87,151,223,274–279 causing loss of volume, 
and chronic microvascular disease, or ischemia,135,220,280 caus-
ing loss of cortical-to-subcortical connections,248 occasionally 
with findings as those in DBT.220,223,281,282
Associations between hypovitaminosis 
B12 or HHcy and cognitive impairment
HHcy, with hypovitaminosis B12, are common findings in 
the evaluation of MCI,59,283–288 AD,43,60,61,82,111,222,276,284,289–291 
VaD,43,61,145,276,284,292 and other dementia subtypes.90,282,293,294 
This raises the question of whether or not these findings 
are the cause of, result of, or unrelated to the disease 
process. Although multiple retrospective and cross-sectional 
studies find associations between hypovitaminosis B12 
and HHcy and cognitive impairment with or without 
dementia,28,39,43,59–61,82,90,111,145,186,196,222,276,283–306 cohort studies 
are required to provide evidence that hypovitaminosis B12 
or HHcy are risk factors for cognitive dysfunction. Eigh-
teen106,136,252,258,301,307–320 of 22 cohort studies demonstrate 
HHcy either increases the risk for cognitive impairment or 
development of dementia. Depending upon whether plasma 
Hcy levels increase or decrease over time, the degree of 
change either increases the risk for developing dementia313 or 
decreases the risk for poorer memory performance,316 respec-
tively. The greater the baseline plasma Hcy level, the faster 
the rate of cognitive decline.320 However, one study found 
that the elevated plasma Hcy risk for developing dementia 
diminished when controlling for low serum folic acid.301 
Four321–324 of 22 cohort studies conclude Hcy is not a factor 
in the development of MCI or dementia, although outcome 
assessment may have been a methodological weakness in 
one of these.324 One cohort study325 concludes HHcy is a 
consequence of the development of cognitive impairment. 
Most,222,276,316,326–328 but not all,329 studies find HHcy is asso-
ciated with intensity, rather than duration, of illness in AD. 
Thus, evidence that HHcy increases the risk for cognitive 
impairment and dementia usually is consistent and repro-
ducible,233 with HHcy predictably increasing the risk that 
subjects with MCI will progress to dementia.233 With respect 
to the involvement of low vitamin B12, seven cohort stud-
ies308,312,313,330–333 show low vitamin B12 either increases the 
risk for cognitive impairment or development of dementia, 
while eight13,325,334–339 show no increased risk. Paradoxical 
findings in these studies include modest increases in serum 
B12 levels over time may increase the risk for dementia313 
and individuals with normal serum B12 levels having a higher 
incidence of AD compared to those with low serum B12 lev-
els.13 Thus, evidence that low vitamin B12 increases the risk 
for cognitive impairment or dementia is inconclusive. Then 
again, the increased risk may occur in the opposite direction. 
AD may increase the risk for B12 deficiency.340
evaluation
in which patients should vitamin B12 
be routinely assessed?
Guidelines for the workup of dementia are listed in 
Figure 3.4,341 Although practices may range from checking 
serum B12 in all elderly to only particular patients with 
dementia, an evidence-based approach warrants checking 
serum B12 in all patients with MCI and mild to moder-
ate dementia of two years or less duration. It is especially 
useful to assess serum B12 levels in all patients with MCI, 
because many will ultimately advance to dementia, where 
there may be a window of opportunity when vitamin B12 
treatment of B12 deficiency-related cognitive dysfunction 
is potentially beneficial. Additionally, serum B12 should 
be checked in all patients with (1) history of gastric bypass 
surgery, partial or total gastrectomy, terminal ileum disease 
or resection, or pancreatic insufficiency,14,20,33,200 (2) chronic 
use of levodopa, histamine type-2 (H2) receptor blockers, or 
protein pump inhibitors (PPIs),22,33,51,54,342–345 or (3) findings 
suggestive of (a) behavioral and psychological symptoms of 
dementia (BPSD), (b) SCD, including paresthesias, ataxia, 
or loss of position or vibratory senses, or (c) pernicious 
anemia (PA), including low hemoglobin (Hgb), elevated 
mean corpuscular volume (MCV), or corpuscular changes on 
peripheral smear.62 If such findings are absent, and patients 
have moderately severe to severe dementia of longer than 
two years duration, then universal recommendations1–4 of Neuropsychiatric Disease and Treatment 2010:6 166
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Guidelines for the workup of dementia, adapted from the American Academy of Neurology
Guidelines on Dementia, 2004. 
(1) The DSM-IIIR definition of dementia is reliable, and its use is appropriate. 
(2) The DSM-IV or the NINCDS-ADRDA diagnostic criteria for DAT and CJD have sufficient
      reliability and validity, and their use is appropriate. 
(3) VaD, DLB, and FTD should be excluded, but the current diagnostic criteria for those diseases 
      have imperfect reliability and validity.
(4) Screening for depression is indicated.
(5) Structural neuroimaging, with either a noncontrast CAT scan or MRI scan of the brain, in the initial 
      evaluation of patients with dementia, is appropriate in order to detect lesions that may result in cognitive
      impairment. 
(6) Evidence supports the following tests in the routine evaluation of the demented patient: 
(a) Complete blood count 
(b) Liver panel (or liver function test) 
(c) Renal panel (or serum electrolytes, glucose, blood urea nitrogen, and creatinine)
(d) Serum B12 Level
(e) Thyroid-stimulating hormone (or thyroid function test) 
(f)  Urinalysis
(7)  Evidence indicates the following tests should not be included in the routine evaluation of the
      demented patient:  
(a) Screening for syphilis (unless patient has risk factors such as living in a high-
      incidence region or engaging in behaviors at high risk for syphilis)
(b) Linear or volumetric MRI or CAT measurement strategies
(c) SPECT
(d) Genetic testing for DLB or CJD
(e) APOE genotyping for AD
(f)  EEG
(g) Lumbar puncture (unless presence of metastatic cancer, suspicion of CNS infection,
(8) At this time, there is not enough evidence to support or refute the use of the following tests:
(a) PET
(b) Genetic markers for AD not listed above
(c) CSF or other biomarkers for AD
(d) Tau mutations in patients with FTD
(e) AD gene mutations in patients with FTD
unusual dementia, immunosuppression, or suspicion of CNS vasculitis)
reactive serum syphilis serology, hydrocephalus, age under 55, rapidly progressive or 
Figure 3 Guidelines for the workup of dementia.
Note: excellent guidelines for the diagnosis of dementia also are available at http://www.cmaj.ca/cgi/content/full/178/7/825.
Abbreviations: AD, Alzheimer’s disease;   APOe, apolipoprotein e; CAT, computerized axial tomography; CJD, Creutzfeldt-Jakob Disease; CNS, central nervous system; 
DAT, Dementia of the Alzheimer Type; DLB, Dementia with Lewy Bodies; DSM-iiir, Diagnostic and Statistical Manual of Mental Disorders-III-Revised; DSM-iv, Diagnostic and 
Statistical Manual of Mental Disorders-IV; eeG, electroencephalogram; FTD, frontotemporal dementia; Mri, magnetic resonance imaging; NiNCDS-ADrDA, National institute of 
Neurologic, Communicative Disorders and Stroke–Alzheimer’s Disease and related Disorders Association; PeT, positron emission tomography; SPeCT, single photon emission 
computerized tomography;   vaD, vascular dementia.Neuropsychiatric Disease and Treatment 2010:6 167
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assessing for and, when found, treating B12 deficiency may 
not be supported by reliable evidence.13,16,24,26,92,187,326,346–364 
H2 receptor blockers and PPIs impair cobalamin absorp-
tion;18,22,33,365,366 their use is associated with supplemental B12 
initiation.367 Individuals who have had gastric surgery have a 
high prevalence of B12 deficiency,20 and those who have had 
gastrectomies, who are B12-deficient, have a high prevalence 
of cognitive dysfunction and electroencephalographic (EEG) 
abnormalities.332 Therefore, patients prescribed H2 receptor 
blockers or PPIs, and those who have had gastrectomies or 
gastric bypass surgery, require monitoring for hypovita-
minosis B12.368
What test or tests should be ordered, 
and how are inferences made from such testing?
Common tests include the deoxyuridine suppression test 
(dUST), serum B12, serum TC II, plasma Hcy, serum or 
urinary methylmalonic acid (MMA), and the post-methionine 
load test. For convenience, conversion of vitamin B12 units 
(nanograms per liter to picograms per milliliter (pg/mL) and 
pg/mL to picomoles per liter) are available at http://www.cdc.
gov/ncbddd/b12/index.html.
The dUST is probably the most sensitive and specific 
test for assessing functional folate or B12 deficiency.92,369 
Although the test is not fully understood and probably more 
complex than a simple explanation,369 if incubated bone 
marrow cells or peripheral blood lymphocytes have suffi-
cient folate and cobalamin, nonradioactive deoxyuridine is 
believed to suppress the thymidylate synthetase conversion 
of radioactive thymidine into thymidylate, which is a normal 
response, but if cells have insufficient folate or cobalamin, 
nonradioactive deoxyuridine does not suppress the thymi-
dylate synthetase conversion of radioactive thymidine into 
thymidylate, which is an abnormal response.
The most common test is the serum B12 level,15 but 
often it is difficult to determine which serum B12 levels 
represent deficiency states and which do not. When using 
a specific serum B12 cutoff point, for example 200 pg/mL 
or less,22,181,200,368 in determining which individuals do and 
do not have B12 deficiency, problems encountered include 
false positives and false negatives.7,15,19,30,33,57,188,370–376 One 
of the reasons for this is because most serum B12 assays 
measure total B12, including free B12 and that bound to 
B12 binding proteins: TC I, also called haptocorrin, TC II, 
simply referred to as transcobalamin, and TC III, which is 
produced by neutrophils.7,371,374 TC I and III are R-proteins 
(R for rapid movement on electrophoresis).7,23,200,377 TC I is a 
storage protein and does not participate in cellular uptake.200,377 
TC II participates in all cellular uptake.7,58,200,371,372,377 TC III 
participates in hepatocyte uptake only.200 TC I and II com-
prise about 80% and 20% of total B12, respectively. Falsely 
low serum B12 occurs in congenital TC I deficiency, where 
TC I is low or absent, but TC II, intracellular B12, and 
hematopoiesis are normal.7,56,200,377 Other causes of falsely 
low serum B12 include folate deficiency, multiple myeloma, 
oral contraceptive use, and pregnancy.7,56 The mechanism 
by which low serum folate causes falsely low serum B12 is 
poorly understood.7,368 Alternatively, low serum cobalamin 
causes methyltetrahydrofolate (CH3-THF) trapping, elevating 
serum CH3-THF, which causes falsely high serum folic acid 
(Figure 1).58,200,372,378 Falsely normal serum B12 occurs in con-
genital TC II deficiency, where TC I is normal, but TC II is low 
or absent, and intracellular B12 is insufficient, causing severe 
megaloblastic, macrocytic anemia.7,56,200,377,379 Other causes of 
falsely normal serum B12 include liver disease, myelopro-
liferative disorders, and intestinal bacterial overgrowth.7,56 
Since serum TC II levels decrease with advancing age, a 
given serum B12 level in an elder may represent a deficiency, 
compared with the same level in a younger adult.30,380 Directly 
measuring serum TC II may be helpful in these cases and 
others.17,38,308,335,351,372,374,380–383
Studies show 10%56,203 to 50%19,368 of truly vitamin B12 
deficient individuals have serum B12 between 200 and 350 pg/
mL, presenting clinicians with a diagnostic challenge. Based 
upon known biochemistry, specific tests can be ordered to help 
with this challenge. Cytoplasmic methylcobalamin is needed 
for MS-catalyzed Hcy methylation to Met, and mitochondrial 
adenosylcobalamin is needed for L-methylmalonyl-CoA 
mutase-catalyzed L-methylmalonyl-CoA conversion to 
succinyl-CoA.7,18,19,20,52,57,58,203 With low cellular B12, these 
reactions are impeded, elevating Hcy in the former and 
L-methylmalonyl-CoA, D-methylmalonyl-CoA, and MMA 
in the latter.18,20,285 Thus, HHcy and hypermethylmalonic aci-
demia (HMMA) are surrogate markers for low vitamin B12 
cellular levels (ie, metabolic B12 deficiency).7,11,15,19–22,30,33,44, 
59,60,188,203,285,294,351,353,368,370,372,373,376,380,384,385 HHcy occurs with 
deficiency of pyridoxine, folate, or vitamin B12;19,306,355,370,386 
usually, only deficiency of vitamin B12 causes HMMA.19,20,370 
Hcy may be the more sensitive and MMA the more specific 
surrogate marker.17,20,38,40,151,156,285,387–389 Either surrogate 
marker is more sensitive than serum B12 in evaluating 
PA,7,19,373,390 and many individuals with HHcy have nor-
mal serum folate and B12 levels.38,39,42 When used alone, 
B12,371,375 TC II,371 Hcy,38 or MMA389 may be insufficient 
as screening tests, but in combination, normal plasma Hcy 
and serum MMA rule out B12 deficiency in virtually all Neuropsychiatric Disease and Treatment 2010:6 168
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cases.19,390 Although the post-methionine load test is twice 
as sensitive as basal Hcy in detecting HHcy in individuals 
with AD,391 it is not recommended as an initial test.17
Most laboratory assays measure total Hcy, including 
reduced and oxidized forms: Hcy representing the former 
and homocystine and mixed disulfides (protein-bound 
Hcy and cysteine-Hcy) the latter.52 Although the upper 
reference limit for plasma Hcy varies according to different 
conditions,17,33 plasma Hcy greater than 14 µmol/L in patients 
with vitamin B12 levels between 201 and 350 pg/mL sug-
gests cellular B12 deficiency.23,41,200,222,252,258,357,387,392 Serum 
B12 greater than 350 pg/mL rules out B12 deficiency in 
almost all individuals.56,200,340 Since tissues store vitamin 
B12 for up to five years18,368,393 and plasma Hcy increases 
only minimally after protein-rich meals,17 serum B12 and 
plasma Hcy may be obtained fasting or nonfasting. Imme-
diate centrifugation, or keeping samples refrigerated or ice 
cooled until centrifugation, prevents spuriously elevated 
Hcy results.17,394,395 Suspected B12 deficiency can be con-
firmed when individuals having characteristic findings, 
including anemia, macrocytosis, corpuscular changes on 
peripheral smear, or signs and symptoms of SCD or periph-
eral neuropathy, improve with vitamin B12 treatment or 
when elevated Hcy or MMA are lowered with vitamin B12 
treatment.19,20,92,135,188,347,362,370,392,396,397 Although not intended 
to replace clinical judgment, suggestions for vitamin B12 
workup and treatment in patients with suspected MCI or 
dementia are presented (Figure 4).
Does the finding of low serum B12 or elevated Hcy 
require evaluation for other medical conditions?
Some authors recommend establishing the etiology of B12 
deficiency as part of the diagnostic approach.5 It is beyond 
the scope of this paper to cover all diagnostic considerations 
in Table 1, but levodopa treatment, folate deficiency, and PA 
are noteworthy.
In Parkinson’s disease (PD) it is the treatment rather 
than the disease that causes HHcy.37,54,294 In such cases, 
HHcy may293,294 or may not398 be associated with cognitive 
impairment. Recall from Figure 1, Met is converted to SAM, 
which is converted to SAH, which is converted to Hcy. SAM 
demethylation to SAH serves as a methyl group donor for the 
biosynthesis of nucleic acids, proteins, phospholipids, and 
catecholamines and the metabolism of drugs and toxins. Cat-
echol-O-methyl transferase (COMT) catalyzes levodopa meth-
ylation to 3-O-methyldopa.344 Increased methyl group demand, 
required for the methylation of levodopa to 3-O-methyldopa, 
favors the conversion of Met to SAM, demethylation to SAH, 
conversion to Hcy, and development of HHcy.51,54,342,344 In a 
cross-sectional study,342 individuals on levodopa alone, com-
pared to those on combined levodopa and COMT inhibitor 
therapy, had higher plasma Hcy levels. However, only one344 of 
three54,343,344 prospective studies showed addition of a COMT 
inhibitor to those on levodopa prevents dopamine-associated 
plasma Hcy elevation or serum B12 reduction.
Since the relationship between folate and vitamin B12 
is biochemically and, in deficiency states, pathologically 
united,285 there are caveats to keep in mind when working 
up and treating folate and B12 deficiencies. When folate and 
B12 deficiencies occur together, monotherapy with either 
folate or vitamin B12 can worsen the manifestations of the 
other vitamin deficiency.7,23,180,285,303,355,371,399,400 Thus, it is 
beneficial to assess serum levels of both vitamins and treat 
whichever deficiency occurs. Although PA and SCD share 
the common etiology, type A (autoimmune) chronic atrophic 
gastritis, with vitamin B12 malabsorption, they have distinct 
pathophysiologies.18,201 In the methionine cycle, folate- and 
vitamin B12-dependent MS catalyzes Hcy methylation to 
Met, as CH3-THF, serving as the methyl group donor, is 
demethylated to THF.47,52,58,151,200 Impairment of this reaction 
causes defective DNA synthesis, leading to megaloblastic, 
macrocytic anemia (ie, PA).21,58 Supplemental folic acid can 
override the impairment, restoring DNA synthesis and nor-
malizing erythropoiesis.58,401 Furthermore, in the methionine 
cycle, Met is adenosylated to SAM, which is demethylated 
to SAH, which is deadenosylated to Hcy.58 Impairment of 
SAM demethylation to SAH impedes methylation reactions, 
leading to vacuolar demyelination, axonal degeneration, and 
neuronal death (ie, SCD).21,58 Supplemental folic acid cannot 
override the methylation impairment, resulting in progressive 
neuropathology and neuronal death.58 Treating a combined 
folate and B12 deficiency with folic acid alone may correct 
hematological abnormalities, but not neurological abnormali-
ties, and can aggressively worsen B12-deficient neurological 
sequelae.7,18,19,23,200,203,355 Thus, B12 deficiency should be ruled 
out before correcting folate deficiency.
When folate and vitamin B12 are in balance, increased 
serum folate levels are associated with decreased plasma Hcy 
and serum MMA levels, but when vitamin B12 is underrep-
resented, increased serum folate levels are associated with 
increased plasma Hcy and serum MMA levels.285 Also, higher 
folate states require relatively higher vitamin B12 levels 
than normal folate states to protect against metabolic B12 
deficiency.285 Therefore, the borderline (201–350 pg/mL) 
serum B12 range may be higher in the presence of high 
folate states.Neuropsychiatric Disease and Treatment 2010:6 169
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Suggestions for vitamin B12 workup and treatment in patients with suspected neuropathology
A. Check serum B12 level when patients have any of the following:
(1) Neurological symptoms suggesting subacute  combined degeneration of the cord or
      autonomic, optic, or peripheral neuropathy 
(2) Abnormal signs including red, beefy tongue, paresthesias, ataxia, or loss of position or 
      vibratory senses 
(3) Mild cognitive impairment or dementia of mild to moderate intensity or two years or 
      less duration 
(4) History of abnormal laboratory results including low Hgb, high MCV, or peripheral
      smear showing corpuscular changes (eg, macrocytes and hypersegmented neutrophils) 
(5) Malnutrition 
B. If serum B12 level has not been assesses in the past, it is useful to check a serum B12 level
     when patients have any of the following. 
(1) Behavioral and psychological symptoms of dementia
(2) History of gastric bypass surgery, stomach resection, terminal ileum disease or
      resection, or pancreatic insufficiency 
(3) Long-term treatment with levodopa, histamine type 2 receptor blocker, or protein
      pump inhibitor 
(4) Findings of leukoaraiosis on brain imaging studies
C. If A (1) or A (2) are applicable and recent CBC is not available, check CBC. If A (1) or A (2) are
    applicable and CBC reveals low Hgb or high MCV, these findings suggest PA may be present. 
D. If serum B12 level is level is �200 pg/mL, check antiparietal cell and anti-intrinsic factor  
    antibodies. If both are negative, then there is low likelihood that the patient has PA. If both are  
    positive, then there is high likelihood that the patient has PA. 
E. If serum B12 level is level is �200 pg/mL and antiparietal cell and anti-intrinsic factor antibodies  
    are incongruent (ie, one is positive, but the other is negative), check the serum gastrin level. If
    elevated, then there is high likelihood that the patient has PA. 
F. If serum B12 level is 201 to 350 pg/mL, then check plasma Hcy. 
(1) If plasma Hcy �14 µmoles/L, there is low likelihood for metabolic B12 deficiency.
(2) If plasma Hcy �14 µmoles/L, there is high likelihood for metabolic B12
      deficiency. 
G. Initiate vitamin B12 treatment in those cases where serum B12 levels are 200 pg/mL or less
    and those where serum B12 levels are 201–350 pg/mL with plasma Hcy greater than 14 µmol/L. 
H. If anemia is severe, consider a dosage regimen similar to that made by American Regent, a
    manufacturer for Cobalamin Injection: 100 µg daily for one week, then every other day for two   
    weeks, then every third day for three weeks, then monthly thereafter, by IM or deep SC injection.* 
    One may consider changing from parenteral to oral therapy (as in paragraph I below) after 
    hematological abnormalities return to normal, rather than monthly vitamin B12 injections. If
    vitamin B12 deficiency is due to PA, supplemental B12 therapy is continued for life.   
 I. If anemia is less severe or absent, other preferred dosage regimens, including
    cyanocobalamin 1,000 µg PO daily, are more preferable and potentially more effective. Other
    common practices  include cyanocobalamin 1,000 µg IM daily for one week, then weekly for one
    month, then monthly thereafter.    
J. Since folate and B12 deficiencies often occur concomitantly, checking serum folate levels also
    may be useful whenever B12 deficiency is suspected. 
Figure 4 Suggestions for vitamin B12 workup and treatment in patients with suspected neuropathology.
Notes: *Studies have reliably shown that PO cyanocobalamin therapy is another option.
Abbreviations: µmol/L, micromoles per liter; CBC, complete blood count; Hcy, homocysteine; Hgb, hemoglobin; iM, intramuscular; MCv, mean corpuscular volume; PA, perni-
cious anemia; pg/mL, picograms per milliliter; PO, oral; SC, subcutaneous.
In what was described as the most severe neuropathic 
epidemic of modern times,402 between 1991 and 1993 more than 
50,000 Cubans developed peripheral neuropathy, associated 
with reduced nutrient intake of group B vitamins,403–409 in the 
setting of strict embargos and economic deterioration.404,405,407,408 
Although widespread distribution of group B vitamins404,406,407,409 
and government-mandated folic acid fortification404,410 curbed 
the epidemic,404,406 some speculate that endemic subclinical Neuropsychiatric Disease and Treatment 2010:6 170
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group B vitamin deficiencies, coupled with Helicobacter 
pylori (H. pylori) infections, are responsible for the higher 
prevalence of dementia in Cuba compared with other Carib-
bean countries.404 Before and after the Cuban epidemic, in 1976 
and 1995, researchers411,412 discovered that folate deficiency 
and relatively high, compared with relatively low, Hcy levels 
in pregnant women are associated with neural tube defects 
(NTDs) in infants born to such women, findings that have 
since been replicated.7,18,52,355,393,413,414 Since supplemental folic 
acid during pregnancy decreases the risk for such abnormali-
ties,415–420 in 1998 the United States Food and Drug Administra-
tion (FDA) and Health Canada required wheat and other grain 
products to be fortified with folic acid.35,58,421–423 To date, more 
than 50 countries have mandated folic acid fortification.410,420 
It is largely accepted that high-dose folic acid may mask B12 
deficiency. It is less clear whether or not low dose folic acid 
masks B12 deficiency.285,401 Although the United States FDA 
requires 140 µg of folic acid per 100 g of grain or flour,424,425 
an amount chosen because it was considered high enough to 
prevent NTDs, but low enough to not mask B12 deficiency, 
some have advocated increasing this amount.426 Due to insuf-
ficient sensitivity, neither Hgb nor MCV are useful in ruling 
out B12-deficient dementia or SCD.7,13,33,58,124,289,300,371,373,378,385,427 
Although the complete blood count (CBC) is part of routine 
diagnostic testing for dementia,368 additional vigilance is 
needed,20,58,381,428 especially in the era of folic acid fortification. 
In B12 deficiency, supplemental folic acid may protect against 
anemia, but not neurodegeneration;19,52,371 thus, the CBC alone 
may become even less sensitive in evaluating B12-deficient 
psychiatric and neurological abnormalities.
Further evaluation to rule out type A chronic atrophic 
gastritis, or PA,181,429 might be warranted because of increased 
risk for gastric cancer, where radiographic or endoscopic 
screening is useful, especially in cases of MCI and early 
dementia.15,18,33,200,201 Thus, it is useful to obtain additional 
testing when B12-deficient dementia occurs with anemia, 
macrocytosis, corpuscular changes on peripheral smear, or 
signs and symptoms of SCD or peripheral neuropathy.7 When 
B12-deficient dementia occurs in the absence of such find-
ings, the decision to rule out type A chronic atrophic gastritis 
may be made on a case by case basis.
Although PA, or type A chronic atrophic gastritis,181,429 is 
often cited as the most common cause of low serum B12,7,18,19,33, 
49,56,58,180,201,390 emerging evidence suggests dissociation between 
PA and B12-deficient dementia.10,13,15,17–19,21,30,32,33,45,47–49,56,58,91–93, 
146,180,190,200,201,203,290,350,368,371,373,376,393,427–434 Thus, B12-deficient 
dementia may be subdivided into B12-deficient dementia with 
PA and B12-deficient dementia without PA. Studies support 
the postulate that these two disease states are different.10,13–15,
17,19,21,25,30,32,33,45,47–49,58,91–93,146,190,201,203,289,290,350,368,427,429,431–435 They 
appear to have different etiologies, pathophysiological find-
ings, prevalences, and responses to treatment.
B12-deficient dementia with PA and B12-deficient 
dementia without PA have separate etiologies, whereby the 
former is caused by type A chronic atrophic gastritis181,429 
and the latter is generally caused by type B (nonautoim-
mune) chronic atrophic gastritis, age-associated decrease 
in hydrochloric acid production, or decreased vitamin B12 
ingestion.9,10,14,17,21,22,30,45,47,49,58,91,92,203,368 Type B chronic atro-
phic gastritis and age-associated decrease in hydrochloric 
acid production cause food-cobalamin malabsorption.30 
Less established causes of relative B12 deficiency include 
impairment of vitamin B12 transfer, from capillaries to 
CSF436 and from CSF to neurons,382 and vitamin B12 
hyperconsumption,54,63,340,342 inactivation,146 or destruction.290 
Type A chronic atrophic gastritis is due to antiparietal cell 
and anti-intrinsic factor antibodies,15,33,58,181,201,203,429 which 
occur in 90% and 55% of cases, respectively,7,203 causing 
parietal cell insufficiency and intrinsic factor dysfunction, 
sparing the antrum.33,58,201 Type B chronic atrophic gastri-
tis is usually caused by H. pylori infection, involving the 
antrum.15,58,201,203 This is especially worth mentioning, because 
gastritis involving both body and antrum437 and H. pylori 
infection, confirmed by serological,437–439 histological,437,438,440 
and rapid urease438 tests, is significantly more prevalent in 
individuals with MCI437 and AD438–440 compared to controls. 
In those with MCI, there is a correlation between serum anti-
H. pylori immunoglobulin G concentration and degree of 
cognitive impairment,437 which may be mediated by elevated 
Hcy levels.437 One study438 showed H. pylori eradication 
improved both cognitive and functional measures in patients 
with AD. Since gastrin is secreted by antral G-cells, serum 
gastrin is elevated with type A,378 but low with type B,21 
chronic atrophic gastritis.
B12-deficient dementia with and without PA have separate 
pathophysiological findings, where myeloneuropathy is 
characteristic and macrocytosis or anemia are present in the 
former,181,190,429 but myeloneuropathy may be rare19 and macro-
cytosis and anemia are often absent13,19,25,30,92,146,289,290,350,427,431–433 
in the latter. Neuropathy associated with PA classically 
involves disease progression, beginning in the cervicotho-
racic region of the spine,202,441 with upper extremity find-
ings classically occurring before lower extremity findings, 
followed by peripheral nerve involvement, and lastly, if at all, 
brain involvement.23,200,203 Dementia is believed to be a late 
and rare finding of neuropathy associated with PA.19,25,48,203,290 Neuropsychiatric Disease and Treatment 2010:6 171
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Alternatively, dementia with B12 deficiency often occurs 
independently from PA.13,25,146,290,427,432,433
B12-deficient dementia without PA is relatively 
common,25,146,290,427,432,433 but B12-deficient dementia with 
PA is considered rare,14,19,25,30,32,48,93,203,290,427,432 where it 
causes only a small fraction of B12 deficiency in demented 
individuals.14,25,30,32,93,290,427,432 PA incidence peaks late in 
midlife,181,429 while dementia incidence increases with 
age.233 Both chronic atrophic gastritis type A and B are 
characterized by low pepsinogen I/pepsinogen II ratios and 
achlorhydria;7,15,21,22,33,378 however, low pepsinogen I/pepsino-
gen II ratios occur in roughly 30% of elderly populations378 and 
PA occurs in only about 2%,23,428 suggesting the majority of 
cases with low ratios are caused by factors other than PA.
Meta-analyses or systematic reviews confirm that HHcy is a 
risk factor for AD,111,233 but they also confirm that vitamin B12 
treatment of B12-deficient dementia is ineffective for improv-
ing cognitive function.16,348,355 Thus, B12-deficient dementia 
without PA and B12-deficient dementia with PA have distinct 
responses to supplemental B12 treatment, where it appears 
that moderately severe to severe dementia does not improve 
in the former,13,15,16,24,26,33,92,187,326,349,350,355,356,358,359,362 but may 
improve in the latter.185,190,199,429,434,435 The apparent dissocia-
tion of hematological findings and neurocognitive impairment 
provides additional support to the postulate that B12-deficient 
dementia with or without PA represent two separate disease 
states. Progressive neurocognitive decline often occurs in the 
presence of normal Hgb and MCV , where one or both values 
are normal in many individuals with B12-deficient demen-
tia13,33,124,188,200,433 or neurological abnormalities.18,20,124,180,188,373 
When anemia is absent, Hgb is indirectly proportional to cogni-
tive function,18,19,200 and when present, it is an inconsistent risk 
factor for cognitive dysfunction.92,430 Neurological impairment 
occurring concomitantly with anemia is more likely to improve 
with supplemental B12 therapy in those cases where the anemia 
is more severe and less likely to improve where the anemia is 
less severe.180,393 With supplemental B12 therapy, increased 
reticulocytosis occurs within one week,376,393 but neurological 
improvement may require six months or longer.180,393 Vitamin 
B12 supplementation reverses hematological abnormalities 
in almost all patients,15,33,185,362 may improve neurological 
abnormalities in roughly one-half,15,33,185 and arrests or reverses 
dementia in only very few.13,15,16,24,26,33,92,187,326,347,349,350,355,361,362
In B12 deficiency dementia with versus without PA, there 
appear to be different manifestations, need for further workup, 
and responses to treatment. Therefore, when findings include 
low serum B12 or elevated Hcy, it is useful to rule out PA. In 
the workup for type A chronic atrophic gastritis, assessment of 
antiparietal cell and anti-intrinsic factor antibodies is an initial 
option.32,181,368,429 Since the former are sensitive, occurring in 
up to 10% of elderly populations,56 and the latter are specific, 
the absence of antiparietal cell antibodies suggests low likeli-
hood,7 while the presence of anti-intrinsic factor antibodies 
suggests high likelihood,7 for type A chronic atrophic gastritis. 
If antiparietal cell antibodies are present and anti-intrinsic 
factor antibodies are absent, assessment of serum gastrin 
levels is a further option.7,33 Type A and B chronic atrophic 
gastritis also can be distinguished by endoscopy with muco-
sal surface biopsy.7,181,429 Although Schilling’s test has been 
largely supplanted by the aforementioned tests,203,368 it may be 
useful if such tests are unremarkable or equivocal.434 How-
ever, decreased vitamin B12 ingestion9,47 and food-cobalamin 
malabsorption9,45,49 are common causes of low serum B12 in 
elderly populations, and Schilling’s test is most often negative 
(ie, step one results are normal) in these conditions.25,33,93,203
When vitamin B12 deficiency is found in dementia, 
is dementia of the Alzheimer’s type a compatible 
diagnosis?
AD is diagnosed by tissue pathology. According to the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (DSM-IV-TR), DAT is essentially a 
diagnosis of exclusion, after other causes of dementia, including 
B12 deficiency, have been ruled out, thus dichotomizing demen-
tia due to B12 deficiency and DAT. Although two studies359,442 
support this dichotomy, most studies13,26,82,222,333,336,382 suggest 
DAT occurs with or without B12 deficiency. When MCI 
and various subtypes of dementia are compared with one 
another, similar concentrations of serum B12 and Hcy are 
observed.276,284,443 When B12-deficient dementia is compared to 
other subtypes of dementia, similar rates of decline are observed 
across almost all measured outcomes.336,350,444 Nonetheless, 
there is likely a DAT subgroup, having low serum B12427,445 
and perhaps elevated platelet monoamine oxidase (MAO) 
activity.29 Since B12 deficiency dementia with PA may arrest 
or reverse with treatment190,429,434 and B12 deficiency dementia 
without PA is usually progressively neurodegenerative despite 
treatment, the presence of PA would suggest dementia due to 
B12 deficiency, while its absence would suggest DAT.446
Treatment
Based on the benefit-to-risk ratio in treatment 
of dementia, if vitamin B12 deficiency is determined, 
should supplemental B12 be initiated?
Vitamin B12 treatment is considered one of the safest medical 
treatments available.447 Although severe adverse events are Neuropsychiatric Disease and Treatment 2010:6 172
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very rare, those reported include anaphylactic shock and death 
with administration of parenteral vitamin B12, hypokalemia 
with sudden death in conditions of severe anemia, and severe 
and sudden optic atrophy in those with Leber’s hereditary optic 
neuropathy.448 Other adverse events include polycythemia, 
thrombosis, pruritus, rash, skin eruptions449 congestive heart 
failure, diarrhea, edema, and swelling. One randomized con-
trolled trial (RCT)347 found a greater prevalence of depression 
in the treatment group, who received high-dose pyridoxine, 
folate, and vitamin B12, than in the placebo group.
Although no overdosage has been reported, in treating 
hypovitaminosis B12 with supplemental B12, there is a fine 
line between help and harm. The serum cobalamin-plasma 
Hcy concentration–response curve appears curvilinear.17 As 
serum cobalamin increases from the lowest detectable level 
to 950 pg/mL, plasma Hcy decreases, but as serum cobala-
min further increases from 950 pg/mL to 1,350 pg/mL, 
plasma Hcy begins to rise. One cohort study,386 found a 
dose-dependent association between increasing serum B12 
levels and incidence of coronary artery disease (CAD) 
and mortality, where each 100 pg/mL increase in serum 
cobalamin was associated with a 10% increased incidence 
for such events. One RCT450 found that low-dose pyridoxine, 
folic acid, and vitamin B12 treatment decreased the risk for 
stroke, CAD events, and death, while moderately high dose 
pyridoxine, folic acid, and vitamin B12 treatment did not. 
Although the earliest two451,452 of eight other RCTs showed 
combined pyridoxine, folic acid, and vitamin B12 treat-
ment decreased morbidity in individuals with or at risk for 
CAD, the later six453–458 failed to validate these findings, and 
four454,456–458 of the six showed treatment potentially increased 
the risk for harm. One of these RCTs455 was prematurely 
terminated due to potential risk for harm demonstrated by 
group B vitamin treatment.454 Therefore, some authors386,454 
suggest supplemental B12 should not be administered 
unless B12 deficiency is present, and when present, only 
enough supplemental B12 should be administered to cor-
rect the deficiency. Parenthetically, meta-analyses of folic 
acid treatment, aimed at lowering HHcy, show mixed results 
in terms of whether or not treatment decreases the risk for 
stroke.459,460 Since most prospective studies show supple-
mental B12 does not improve cognitive function or prevent 
dementia in cognitively intact individuals,306,354,360 including 
those with hypovitaminosis B12351,353 or HHcy,357 it is not 
recommended401 for these purposes.
HHcy increases the risks for birth defects, cognitive 
dysfunction, dementia, cerebrovascular disease, stroke, 
CAD, MI, peripheral vascular disease, venous thrombosis, 
osteoporosis, hip fractures, and death.21,39,279,386,461–468 
Benefits of treating B12 deficiency include lowering Hcy 
levels,19,21,47,135,198,326,347,351,357,360–362,397,469 lowering Aβ peptide 
levels,470 decreasing tau hyperphosphorylation,132 anti-
inflammation,471 neuroprotection,471 reduction of MAO 
activity,29 and causing the BBB to be less leaky.469
It may not be feasible to perform a meta-analysis on studies 
that have ascertained whether or not vitamin B12 treatment is 
associated with improved cognitive function or prevention of 
dementia due to the heterogeneity of these studies (Table 2). 
Published studies include multiple designs (eg, case-control, 
other retrospective studies, RCTs, and other prospective 
studies), subjects (eg, those who are healthy, ill, community-
dwelling, residents of tertiary care facilities, with and without 
cognitive dysfunction, and with and without vitamin B12 
deficiency), interventions, including vitamin B12 alone or in 
combination with other drugs or dietary supplements, type of 
vitamin B12 administered, and route of administration.
Traditional recommendations of assessing for and, when 
found, treating B12-deficient dementia are supported by case-
control studies,350,359 retrospective series,49,180,188,435,472 and case 
reports,190,429,434 where B12 deficiency was specifically caused 
by PA. Evidence supporting these recommendations appears 
to diminish with many RCTs,16,185,198,298,306,326,347,348,351–353,355,35
7,360,361,364,473,474 clinical trials (CTs),13,24,185,187,199,346,356,362,397,469 
and other prospective studies26,92,349,358,475 (Tables 3a and b). 
Twelve16,306,326,347,351–353,355,357,360,361,364 of 16 RCTs found supple-
mental B12 therapy was of no benefit for improving cognitive 
function. Four185,198,473,474 of 16 RCTs found supplemental B12 
therapy was beneficial for improving cognitive function; 
however, subjects in these studies included nondemented, 
healthy adult women,473 individuals with schizophrenia 
and HHcy,198 and individuals with dementia, irrespective of 
serum B12 levels, treated with multiple vitamins and other 
dietary supplements.474 The design of one of these stud-
ies185 did not include a separate control group. In all other 
RCTs of individuals with hypovitaminosis B12,16,351,353,355 
HHcy,357 HMMA,352 dementia,16,326,347,355,361 or at risk for 
dementia,326,348,352,360,364 vitamin B12 treatment group results 
were no better than placebo group results. Nonetheless, the 
results from the RCTs may not generalize to all patients. Five 
of these306,351,353,357,360 did not examine subjects with MCI or 
dementia, three16,326,355 may have included subjects in various 
dementia stages, and six appear to have enrolled subjects, 
with either normal347,361 or irrespective306,326,360,364 of baseline 
folate and vitamin B12 statuses.
Although  few  included  control  groups,198,199,473,474 
CTs  and  other  prospective  studies  with  positive Neuropsychiatric Disease and Treatment 2010:6 173
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Table 2 Examples of multiple binary variables in studies examining efficacy of B12 treatment on cognition
No   Time course   Type of study  Absence/presence of  
cognitive dysfunction
B12 status*  Study results; author,  year 
1 retrospective  
and cross-sectional
Not case control Absent Unknown Positive; La rue, 1997
2 Not case control Absent Low Positive; Healton, 19911
3 Not case control Present Low Positive; Lindenbaum, 1988 
el Otmani, 20082 Fox, 19753 
Healton, 19911
4 Case control Absent Normal Negative; Lin, 20084
5 Case control Present Low Negative; eastley, 20005
6 Case control Present Low Positive; eastley, 20005 
Osimani, 20056
7 Not randomized controlled trial Absent Low Positive; van Asselt, 2001
8 Prospective Not randomized controlled trial Present Unknown Positive; ikeda, 19927
9 Not randomized controlled trial Present Normal Positive; Lehmann, 20038
10 Not randomized controlled trial Present Low Negative; Carmel,1995 
Crystal, 19949 Cunha, 199010 
Kwok, 200811 Teunisse, 199612 
van Dyck, 200813
11 Not randomized controlled trial Present Low Positive; Abyad, 200214 Cunha, 
199515 Kalita, 2008 Kwok, 
200811 Martin, 199216 Nilsson, 
200117
12 randomized controlled trial Absent Unknown Negative; Stott, 200518 
Wolters, 2005
13 randomized controlled trial Absent Unknown Positive; Bryan, 2002
14 randomized controlled trial Absent Normal Positive; Levine, 200619
15 randomized controlled trial Absent Low Negative; eussen, 2006 Kwok, 
1998 McMahon, 2006
16 randomized controlled trial Present Unknown Negative; van Uffelen, 2008
17 randomized controlled trial Present Unknown Positive; remington, 200920
18 randomized controlled trial Present Normal Negative; Aisen, 2008 Clarke, 
200321 Sun, 2007
19 randomized controlled trial Present Low Negative; Clarke, 200321 
Fourniere, 1997 Hvas, 2004 
Seal, 2002
20 randomized controlled trial Present Low Positive; Bolaman, 200322
Notes: 1, Subjects had nervous system involvement; 2, N = 1; 3, N = 1; 4, sample consisted of asymptomatic nursing home males; 5, results were negative for subjects with dementia, 
and positive for those with mild cognitive impairment; 6, baseline neuropsychiatric tests determined those who did not improve from those who improved; 7, B12 status was 
not a major factor mentioned in the methods or results sections, treatment consisted of intravenous mecobalamin; 8, subjects had normal vitamin B12, hyperhomocysteinemia, 
and mild cognitive impairment at baseline, and there were no subjects who progressed to dementia; 9, N = 3; 10, N = 13; 11, delirium improved, but dementia did not improve; 
12, N = 26; 13, N = 28; 14, shorter duration of cognitive dysfunction was associated with greater response to B12 treatment; 15, outcome was obtained in 19/46 patients, 
16/19 worsened, and 3/16 improved with B12 therapy, those who improved had mild dementia of less than two years duration; 16, individuals who were symptomatic less than 
12 months improved with B12 therapy; 17, those with mild-moderate dementia and those with hyperhomocysteinemia improved with supplemental B12 therapy; 18, subjects 
were elders with ischemic vascular disease; 19, subjects had schizophrenia; 20, the dietary supplement also contained N-acetylcysteine, S-adenosylmethionine, and multiple 
other ingredients; 21, the sample presumably included those with normal and low serum B12; 22, all subjects had pernicious anemia, oral was compared with intramuscular 
cyanocobalamin. *Binary variables include B12 status: known versus unknown, and known-normal versus known-low.
results24,185,187,198,199,346,356,358,397,469,473–475 show cognitive improvement 
may be associated with five factors: Hcy state,37,57,200,358,397 
disease duration,18,24,30,180,346,356 disease intensity,24,180,350,358,359 
and treatment type,474,475 as shown in Table 4.17,24,37,58,146,180,290, 
306,346,350,351,353,356–359,361,473–495 The fifth factor, and perhaps the 
most striking, is whether or not the B12 deficiency-associated 
cognitive dysfunction is due to PA. If so, then these individuals 
may respond remarkably well to supplemental B12 treatment, 
regardless of the severity of the dementia.185,190,429,434 Parentheti-
cally, all RCTs show supplemental folic acid is no better than Neuropsychiatric Disease and Treatment 2010:6 174
Werder Dovepress
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placebo at improving cognitive function in individuals with 
dementia.348,355,361,496
BPSD include symptoms and signs of disturbed 
behavior, mood, psychomotor activity, and thought 
content (eg, delusions and hallucinations) in patients with 
dementia. Exogenous SAM improves depression in patients 
with PD481 and other conditions.494,495 In individuals with 
AD, those with HHcy have increased EEG slow wave 
activity (ie, increased theta and delta waves) compared 
to those without HHcy.184,257 In nondemented individuals, 
lowering plasma Hcy levels with vitamin B12 treatment 
reverses such EEG findings.184,397 Accordingly, prospective 
studies of individuals with B12-deficient dementia show 
patients with delirium187 or psychoses359 improve with 
vitamin B12 supplementation. In demented individuals, 
prospective studies show vitamin B12 supplementation 
enhances vigilance when combined with bright light 
therapy,497 improves mood disturbances,475 but may worsen 
motor performance.353 Although not a consistent find-
ing,187,362 supplemental B12 in B12-deficient dementia may 
be beneficial for some patients with BPSD.359,475 Independent 
from serum folic acid and B12 levels, an association was 
found between HHcy and schizophrenia;498 in spite of the 
HHcy association being independent from group B vitamins 
in that study, another study198 showed combined pyridoxine, 
folic acid and vitamin B12 treatment in individuals with 
HHcy and schizophrenia improved positive symptoms, 
negative symptoms, and cognitive function. Depression, 
mania, psychoses, and delirium associated with PA or 
hypovitaminosis B12 may improve with supplemental B12 
treatment.181–184,190,191
Considering the potential risks for adverse events, added 
cost, and added administration, and the potential benefit 
for arresting or reversing dementia, if B12 deficiency is 
determined, it should be treated. Vitamin B12 treatment 
should be initiated in those cases where serum B12 levels 
are 200 pg/mL or less and those where serum B12 
levels are 201–350 pg/mL with plasma Hcy greater than 
14 µmol/L.320 Duration of therapy is based on etiology and 
other factors, with an optimum serum B12 not being more 
than 950 pg/mL. In cases of PA, treatment is continued 
for life. In cases of dietary deficiency, low vitamin B12 
in dementia normalizes with dietary correction.14 Possible 
explanations on why dementia does not reverse or arrest with 
supplemental B12 include treatment being an ineffective 
form,146,290 initiation outside of a time course window,30,346,356 
or dementia not solely being caused by PA or low serum 
B12.13,26,82,222,333,336,359,442
How is vitamin B12 deficiency treated?
Since bacteria produce natural forms of vitamin B12, 
which humans ingest by consuming animal products,19,58,201 
strict vegetarians may require oral (PO) vitamin B12 
supplementation.58 The recommended daily allowance 
(RDA) is 2.4 µg daily. 499 Supplemental forms of vitamin 
B12 include cyanocobalamin, used in the United States, 
hydroxocobalamin, used in Europe, and mecobalamin, 
used in Asia.7,361,475 Mecobalamin is a synthetic form of 
methylcobalamin, which is the type of cobalamin utilized 
intracellularly. Although it may be advantageous in cognitive 
improvement or protection,475 it has not been compared with 
cyanocobalamin or hydroxocobalamin in clinical trials, and 
it may not be readily available in many western countries. 
Routes for cyanocobalamin administration include PO, 
sublingual (SL), intranasal (IN), intramuscular (IM), and 
subcutaneous (SC). Although the intravenous (IV) route has 
been used in patients with renal failure,500,501 this route is not 
recommended for general use.448 Compared to PO cyanoco-
balamin, IM and IV cyanocobalamin potentially pose greater 
risks for anaphylaxis. Up to 98% of an IM dose is lost in the 
urine, and even more is lost with an IV dose.387,448 Alterna-
tively, 1% of PO cyanocobalamin is absorbed, throughout 
the gastrointestinal tract, by passive diffusion, independent 
of intrinsic factor.18,52,201,368,387 Thus, 10 µg will be absorbed 
from a 1,000 µg dose, well above the RDA;18,201,502 this 
effect is seen even in those with PA, prior gastrectomies, 
or diseases of the terminal ileum.52,368,387,503 Most physicians 
favor IM over PO routes,20,23,31,203,504 while most patients favor 
PO over IM routes.503,505 Patient preference is supported by 
a CT91 and RCTs31,34,185,392 showing PO cyanocobalamin 
provides equal, if not greater, serum B12 therapeutic levels. 
Since PO cyanocobalamin is as effective as IM cyanoco-
balamin in treating B12 deficiency, and its complications, 
it may be the preferred route of administration, unless there 
is concern regarding PO cyanocobalamin adherence, such 
as dysphagia.19,200,376,505 Variance exists in recommendations 
for dose and administration frequency: common practices 
include cyanocobalamin 1,000 µg PO daily203,503,505 or cya-
nocobalamin 1,000 µg IM daily for one week, then weekly 
for one month, then monthly thereafter.23,185,200,203,346,356,387,393 
Alternative regimens are recommended for those with mani-
festations of severe PA.448
Conclusions
Although this paper represents a synopsis of our current 
understanding between HHcy and hypovitaminosis B12 and 
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Table 4 Factors associated with cognitive improvement in B12 supplementation of B12-deficient dementia
Etiology
  •  Treatment of B12 deficiency caused by pernicious anemia generally is associated with cognitive improvement.
  •  Treatment of B12 deficiency caused by etiologies other than pernicious anemia generally is not associated with cognitive improvement.
Homocysteine state
  •  Presence of hyperhomocysteinemia at treatment onset is associated with improvement, whereas absence is not.37,358
Disease duration
  •  Duration of disease two years or less is associated with improvement, whereas duration of disease more than two years is not.24,180,346,356
Disease intensity
  •    Mild cognitive impairment and mild to moderate dementia are associated with improvement, whereas moderately severe to severe dementia is 
not.24,180,350,358,359
  •    Four306,351,353,357 of five306,351,353,357,473 prospective studies, in individuals without cognitive dysfunction, showed supplemental B12 does not improve 
cognitive function, including in those with hypovitaminosis B12351,353 and hyperhomocysteinemia.357
Treatment type
  •  Compounds
      Glutathionylcobalamin
      •  used by neurons under oxidative stress conditions146
      •  not commercially available146,290
      Cyanocobalamin
      •  not used by neurons under oxidative stress conditions146,290
      •  commercially available
      Hydroxocobalamin
      •  not used by neurons under oxidative stress conditions146,290
      •  commercially available
      Mecobalamin
      •  not used by neurons under oxidative stress conditions146,290
      •  commercially available
  •  Routes of administration
      Cyanocobalamin
      •  can be administered orally, sublingually, intranasally, intramuscularly, subcutaneously, or intravenously
      •  The intravenous route is not advised unless the patient is in renal failure, since more than 98% of an intravenous dose may be lost in the urine.
      Methylcobalamin
      •  Oral doses
        •  do not increase serum or cerebral spinal fluid B12 levels490
        •  do not improve cognitive function or activities of daily living in patients with Alzheimer’s disease361
      •  intramuscular or intravenous doses are required
        •  intravenous doses have been shown to improve cognition, communication, emotions, and memory in patients with Alzheimer's disease.475
  •  Whether or not methyl donors or antioxidants are administered
      N-acetylcysteine, a cell-permeate glutathione precursor,483 when combined with B12, improves cognition in patients with HHcy.474,488
        S-adenosylmethionine may be a useful adjunct for treatment of depression,477–479,485,487 associated with Parkinson’s disease,481 human 
immunodeficiency virus infection,494 and fibromyalgia.495
      Betaine lowers systemic Hcy476,482,491,492 and may delay illness progression in Alzheimer’s disease.486
      •  Homocysteine methylation to methionine occurs by one of two means
            methionine synthetase converting methyltetrahydrofolate to tetrahydrofolate, with methyltetrahydrofolate as the methyl group donor – occurs in all cells
            betaine homocysteine methyltransferase converting betaine to dimethylglycine, with betaine as the methyl group donor17,58,484 – confined to 
the liver and kidneys480,489,493 This may not matter in the treatment of dementia, as a leaky blood brain barrier may allow influx of systemic 
homocysteine.Neuropsychiatric Disease and Treatment 2010:6 182
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contrary results or recommendations.27,41,62,188,340,398,401,506–508 
Possible errors from this review and its conclusions are 
that Medline was the primary database, searches may not 
have captured all relevant studies and case reports, and it is 
presumed that there are unpublished vitamin B12 treatment 
responses. In order to attempt to minimize erroneous con-
clusions, results were crosschecked with Internet searches 
and basic and clinical science textbooks, other Medline 
searches were performed using various search terms, 
and communication took place with experts who care for 
demented patients. Owing to the latter, it is crucial that PA 
be ruled out in all demented patients. Also, the trials that 
have been reported to date may have been of insufficient 
size or duration to determine a beneficial effect.233
Biological data support the notion that ROS generation 
may lead to elevated Hcy, but this may be, at least in part, 
an adaptive mechanism to generate cysteine, which is used 
in the biosynthesis of glutathione,120,509 an antioxidant that 
protects cells from oxidative stress. Biochemical and epide-
miological evidence is convincing that HHcy, with or without 
hypovitaminosis B12, is a risk factor for dementia. Evidence 
is less convincing that hypovitaminosis B12 is a risk fac-
tor for dementia in the absence of HHcy. B12 deficiency 
manifestations are variable and include abnormal psychiatric, 
neurological, gastrointestinal, and hematological findings. 
Radiological images of nondemented and demented indi-
viduals with HHcy frequently demonstrate leukoaraiosis, 
potentially related to BBB dysfunction. Thus, the finding 
of leukoaraiosis on CAT or MRI scan is an indication for 
checking plasma Hcy and serum B12 levels.
Although historically neuropathy related to PA was 
described according to a classical disease progression, patient 
samples now show that symptoms and signs secondary to 
the neuropathy can be variable.180,188 Nonetheless, dementia 
secondary to PA, occurring separately from other manifesta-
tions of SCD or peripheral neuropathy, and in the absence 
of macrocystosis and anemia, may still be considered suf-
ficiently rare to be the basis of case reports.190,199,434
On the one hand, literature suggests assessing serum 
B12 and treatment of B12 deficiency is useful early in the 
course of cognitive dysfunction, for instance, MCI199,350,469 
and mild to moderate dementia of less than two years 
duration.24,180,346,356,358,359 If low serum B12 is determined, 
it may be worthwhile to check for antiparietal cell and 
anti-intrinsic factor antibodies and obtain testing for 
H. pylori, for management and prognostic purposes. On 
the other hand, literature suggests assessing serum B12 and 
treatment of B12 deficiency may not be useful late in the 
course of cognitive dysfunction, for instance, moderately 
severe to severe dementia, if symptoms and signs of SCD and 
peripheral neuropathy, hematological manifestations of PA, 
and other factors listed on Figure 4 are absent. However, if 
one has not inquired about neurological symptoms, examined 
the mouth and tongue, performed a neurological examina-
tion, and obtained a CBC on a moderately-severe to severely 
demented patient, then it could be a ‘medical-legal pitfall’ not 
to check the serum B12 level.62 The suggestions for vitamin 
B12 workup and treatment in patients with suspected MCI 
or dementia are evidence-based. However, since the rate of 
dementia progression is poorly measured and variable and 
there are no specific criteria for vitamin B12 testing, the sug-
gestions are not intended to replace care based upon clinical 
decisions. The serum B12 level remains the standard initial 
test.181 DAT is a compatible diagnosis when B12 deficiency 
is found, unless it is caused by PA. Cyanocobalamin PO is 
favorable over IM, in terms of both therapeutic efficacy and 
patient preference, unless there is concern regarding PO 
adherence.
Since the original observations by Biermer in 1872, to 
the more recent epidemic neuropathy in Cuba, it is evident 
that adequate folate and vitamin B12 function is required for 
physical and mental health. Issues surrounding folate, vita-
min B12, Hcy, and MMA as they relate to health, especially 
microvascular disease and cognitive dysfunction, are high 
interest among researchers and clinicians. Puzzling questions 
remain. Since B12 deficiency can lead to depression, mania, 
and psychoses, should clinicians routinely check serum 
B12 levels in patients with such findings? Among those 
individuals who are B12 deficient, what are the prevalences 
of antiparietal, anti-intrinsic factor, and anti-H. pylori anti-
bodies? Is HHcy a risk factor for other types of dementia, 
such as DBT, dementia due to PD, or dementia with Lewy 
bodies?193,510,511 Since HHcy has been prospectively shown 
to be an ‘independent’ risk factor for dementia, then why are 
Hcy-lowering therapies ineffective, or at best modestly effec-
tive, at preventing or treating dementia? Answers to questions 
such as these may one day unleash knowledge necessary for 
more effective treatment. The notions of age-related, and 
perhaps disease-related, degradation of the BBB and oxida-
tive chemical reactions, generating ROS and elevating Hcy, 
coupled with immune activation, both without and within the 
brain, remain novel areas for further work.120
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